Company name: Zoetis UK Limited
Address: 5th Floor, 6 St. Andrew Street
London EC4A 3AE
Telephone: 0845 300 8034
Fax: 01737 332521
A solution for injection, each 1ml dose containing live attenuated canine parvovirus, NL-35-D strain, low passage ≥ 107.0 CCID50. CCID50 – Cell culture infectious dose-50 Also contains traces of neomycin and gentamycin.
For the active immunisation of healthy puppies and dogs to prevent clinical signs including leucopenia and reduce viral shedding caused by canine parvovirus (type 2a), and to prevent mortality and clinical signs including leucopenia and reduce viral shedding caused by canine parvovirus (types 2b and 2c).
Onset of immunity occurs by approximately 2 weeks after the last dose of the Basic Vaccination Scheme. Onset of immunity for the canine parvovirus component (type 2b) occurs 7 days after a single dose when animals are vaccinated from 9 weeks of age.
The duration of immunity is at least 12 months.
Shake well and immediately inject the entire contents of the vial (1 ml) subcutaneously. Do not use chemically sterilized syringes or needles, as these will interfere with the effectiveness of the vaccine.
Basic Vaccination Scheme:
Puppies younger than 10 weeks of age: Two doses of Vanguard CPV at least 14 days apart. The first dose can be given as young as 6 weeks of age. The second dose should not be given until at least 10 weeks of age.
Puppies 10 weeks of age and older: A single dose of Vanguard CPV, followed by a single dose of Vanguard Lepto ci at least 14 days later.
A single dose of Vanguard CPV to be given annually thereafter.
See Further Information section for more detailed guidance relating to duration of immunity.
Do not vaccinate unhealthy or pregnant animals.
Vaccinated dogs may have a transient swelling 4-6 hours after vaccination which resolves after approximately 7 days. If a systemic anaphylactic reaction occurs (e.g. vomiting) administer adrenaline or an equivalent.
Occasional, transient swellings may occur at the injection site after vaccination with an overdose. No treatment is necessary in most cases of overdose. However, if a systemic anaphylactic reaction occurs (e.g. vomiting) administer adrenaline or an equivalent.
The canine parvovirus vaccinal strain may be shed from vaccinated animals for a number of days following vaccination. However, due to the low pathogenicity of this strain, it is not necessary to keep vaccinated animals separated from non-vaccinated animals.
High levels of maternally derived antibodies (MDA) may interfere with the response to vaccination. Although the vaccine has been shown to be efficacious in the presence of levels of MDA that are likely to be encountered under field conditions, where for any reason it is likely that particularly high levels of MDA against CPV are present, this should be taken into account when planning the timing of vaccinations.
In case of accidental self-injection, wash the area immediately with water. If symptoms develop, seek medical attention showing a copy of the product literature.
Store and transport at +2°C to +8°C. Do not freeze.
No information is available on the safety and efficacy from the concurrent use of this vaccine with any other except vaccines from the Vanguard™ range containing distemper virus, canine adenovirus, canine parainfluenzavirus or leptospira antigens. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be decided on a case by case basis.
Do not mix with any other vaccine or immunological product.
Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant in accordance with national requirements.
For animal treatment only.
Keep out of reach and sight of children.
Packs contain 25 doses of Vanguard CPV. Packs of disposable syringes with needles are also available.
Annual booster vaccination is recommended. However, should Veterinary Surgeons conduct a risk-benefit analysis for individual animals to determine the frequency of revaccination with Vanguard CPV, they should be aware of the following information. Serological data has indicated that most dogs, when given at least the first annual booster, can maintain protective levels of immunity to the parvovirus component of Vanguard CPV for up to 4 years. For further information please contact the company.
Canine parvovirus disease in kennels and pet shops is a problem of intensive husbandry and must be treated as such. Without careful professional attention to management practices in such places, successful disease control may be difficult to achieve.
When used in accordance with the recommended vaccination regime, Vanguard CPV can aid in the reduction of environmental contamination with canine parvovirus.
Change in onset of immunity for CPV type 2b
25 x 1 dose: